Market Cap | 140.47M | P/E | - | EPS this Y | 38.20% | Ern Qtrly Grth | - |
Income | -158.44M | Forward P/E | -6.00 | EPS next Y | 69.80% | 50D Avg Chg | -5.00% |
Sales | - | PEG | - | EPS past 5Y | 63.03% | 200D Avg Chg | -39.00% |
Dividend | N/A | Price/Book | 2.46 | EPS next 5Y | - | 52W High Chg | -80.00% |
Recommedations | 2.00 | Quick Ratio | 1.91 | Shares Outstanding | 179.26M | 52W Low Chg | 30.00% |
Insider Own | 9.81% | ROA | -57.89% | Shares Float | 145.62M | Beta | 2.09 |
Inst Own | 58.20% | ROE | -174.30% | Shares Shorted/Prior | 10.14M/10.79M | Price | 0.78 |
Gross Margin | - | Profit Margin | - | Avg. Volume | 2,316,038 | Target Price | 5.60 |
Oper. Margin | - | Earnings Date | May 11 | Volume | 1,830,878 | Change | -2.86% |
Spectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology and hematology drug products. The company's products under development include Eflapegrastim, a novel long-acting granulocyte colony-stimulating factor for chemotherapy-induced neutropenia; Poziotinib, a novel irreversible tyrosine kinase inhibitor for non-small cell lung cancer tumors with various mutations; and Anti-CD20-IFNa, an antibody-interferon fusion molecule directed against CD20 that is in Phase I development for the treatment of patients with relapsed or refractory non-Hodgkin's lymphoma, including diffuse large B-cell lymphoma. It has co-development, commercialization, and in-license agreements with Hanmi Pharmaceutical Co. Ltd.; a patent and technology license agreement with The University of Texas M.D. Anderson Cancer Center; and in-license agreement with ImmunGene, Inc. The company was formerly known as NeoTherapeutics, Inc. and changed its name to Spectrum Pharmaceuticals, Inc. in December 2002. Spectrum Pharmaceuticals, Inc. was incorporated in 1987 and is based in Henderson, Nevada.
B. Riley Securities | Buy | Mar 21, 22 |
H.C. Wainwright | Buy | Oct 26, 20 |
JMP Securities | Outperform | Sep 17, 20 |
HC Wainwright & Co. | Buy | Aug 3, 20 |
Cantor Fitzgerald | Neutral | Jul 28, 20 |
B. Riley FBR | Buy | Mar 2, 20 |
B. Riley FBR | Buy | Dec 27, 19 |
Guggenheim | Neutral | Dec 27, 19 |
Cantor Fitzgerald | Neutral | Dec 26, 19 |
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
LEBEL FRANCOIS | Chief Medical Office.. Chief Medical Officer | Jun 21 | Sell | 0.82 | 12,763 | 10,466 | 644,790 | 06/23/22 |
Brennan Nora | EVP & CFO EVP & CFO | Jun 21 | Sell | 0.79 | 3,569 | 2,820 | 360,215 | 06/23/22 |
Fischer Seth H. Z. | Director Director | Jun 21 | Sell | 0.785 | 5,711 | 4,483 | 29,066 | 06/22/22 |
Vyas Dolatrai | Other Other | Jun 21 | Sell | 0.785 | 4,283 | 3,362 | 82,063 | 06/22/22 |
Ashton William | Director Director | Jun 21 | Sell | 0.785 | 4,283 | 3,362 | 42,660 | 06/22/22 |
LEBEL FRANCOIS | Chief Medical Office.. Chief Medical Officer | Apr 04 | Sell | 1.38 | 2,572 | 3,549 | 252,513 | 04/05/22 |
LEBEL FRANCOIS | Chief Medical Office.. Chief Medical Officer | Mar 15 | Sell | 0.71 | 50,235 | 35,667 | 255,085 | 03/16/22 |
McGahan Keith M | Chief Legal Officer Chief Legal Officer | Mar 15 | Sell | 0.71 | 30,976 | 21,993 | 244,940 | 03/16/22 |
Riga Thomas J | CEO & President CEO & President | Mar 15 | Sell | 0.71 | 39,185 | 27,821 | 568,800 | 03/16/22 |
GUSTAFSON KURT A | EVP & Chief Financia.. EVP & Chief Financial Officer | Mar 15 | Sell | 0.71 | 36,971 | 26,249 | 317,259 | 03/16/22 |
LEBEL FRANCOIS | Chief Medical Office.. Chief Medical Officer | Feb 23 | Sell | 0.67 | 28,174 | 18,877 | 305,320 | 02/24/22 |
Riga Thomas J | CEO & President CEO & President | Feb 23 | Sell | 0.67 | 38,394 | 25,724 | 607,985 | 02/24/22 |
McGahan Keith M | Chief Legal Officer Chief Legal Officer | Feb 23 | Sell | 0.67 | 28,544 | 19,124 | 275,916 | 02/24/22 |
GUSTAFSON KURT A | EVP & Chief Financia.. EVP & Chief Financial Officer | Feb 23 | Sell | 0.67 | 36,173 | 24,236 | 354,230 | 02/24/22 |
LEBEL FRANCOIS | Chief Medical Office.. Chief Medical Officer | Nov 08 | Sell | 2.19 | 13,363 | 29,265 | 329,166 | 11/10/21 |
LEBEL FRANCOIS | Chief Medical Office.. Chief Medical Officer | Jun 23 | Sell | 4.04 | 10,821 | 43,717 | 340,046 | 06/23/21 |
Riga Thomas J | EVP, COO & CCO EVP, COO & CCO | May 14 | Sell | 3.08 | 5,652 | 17,408 | 406,879 | 05/14/21 |
McGahan Keith M | Chief Legal Officer Chief Legal Officer | May 14 | Sell | 3.08 | 959 | 2,954 | 311,934 | 05/14/21 |
LEBEL FRANCOIS | Chief Medical Office.. Chief Medical Officer | Apr 06 | Sell | 3.28 | 2,150 | 7,052 | 350,867 | 04/06/21 |
McGahan Keith M | Chief Legal Officer Chief Legal Officer | Apr 01 | Sell | 3.25 | 3,939 | 12,802 | 312,893 | 04/01/21 |
McGahan Keith M | Chief Legal Officer Chief Legal Officer | Feb 23 | Sell | 3.68 | 7,295 | 26,846 | 347,512 | 02/23/21 |
Riga Thomas J | EVP, COO & CCO EVP, COO & CCO | Feb 23 | Sell | 3.68 | 10,018 | 36,866 | 454,650 | 02/23/21 |
McGahan Keith M | Chief Legal Officer Chief Legal Officer | Feb 10 | Sell | 3.93 | 4,477 | 17,595 | 244,498 | 02/10/21 |
GUSTAFSON KURT A | EVP & Chief Financia.. EVP & Chief Financial Officer | Jan 20 | Sell | 4.06 | 4,526 | 18,376 | 330,608 | 01/20/21 |
Turgeon Joseph W. | CEO & President CEO & President | Jan 20 | Sell | 4.06 | 7,733 | 31,396 | 370,029 | 01/20/21 |
LEBEL FRANCOIS | Chief Medical Office.. Chief Medical Officer | Nov 09 | Sell | 3.53 | 12,025 | 42,448 | 306,424 | 11/09/20 |